Elite in Eosinophilic Asthma

Peter H. Howarth

London, ENG, GB 
Elite in Eosinophilic Asthma
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Peter Howarth practices in London, United Kingdom. Mr. Howarth is rated as an Elite expert by MediFind in the treatment of Eosinophilic Asthma. His top areas of expertise are Eosinophilic Asthma, Asthma, Chronic Eosinophilic Pneumonia, Simple Pulmonary Eosinophilia, and Endoscopy.

His clinical research consists of co-authoring 204 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles in the study of Eosinophilic Asthma.

Gender
Male

Locations

London, ENG, United Kingdom
Other Locations
Brentford, ENG, United Kingdom
Loughborough, ENG LE113TU, United Kingdom
Middlesex, ENG, United Kingdom
Guy's And St. Thomas' NHS Foundation Trust, Oxford, ENG, United Kingdom
Southampton, ENG, United Kingdom
Cambridge, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

WATCH (Wessex AsThma CoHort of Difficult Asthma): A Longitudinal Cohort Study to Facilitate Better Understanding and Management of Difficult Asthma Encountered in Clinical Practice
WATCH (Wessex AsThma CoHort of Difficult Asthma): A Longitudinal Cohort Study to Facilitate Better Understanding and Management of Difficult Asthma Encountered in Clinical Practice
Enrollment Status: Active_not_recruiting
Publish Date: January 19, 2024
Effect of Clopidogrel on Allergen Challenge in Asthma
Effect of Clopidogrel on Allergen Challenge in Asthma
Enrollment Status: Completed
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drug: Clopidogrel
Study Phase: Phase 2
A Randomised Pragmatic Trial Of Corticosteroid Optimisation In Severe Asthma Using A Composite Biomarker Algorithm To Adjust Corticosteroid Dose Versus Standard Care
A Randomised Pragmatic Trial Of Corticosteroid Optimisation In Severe Asthma Using A Composite Biomarker Algorithm To Adjust Corticosteroid Dose Versus Standard Care
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Other
Study Phase: Not Applicable
View 2 Less Clinical Trials

204 Total Publications

Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year study.
Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year study.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: September 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Howarth's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile